Prostatic Specific Antigen in Prostatic Carcinoma

2015 ◽  
pp. 33-50
Author(s):  
D. Axt-Manz
Keyword(s):  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Specific Antigen

Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma

The Prostate ◽  
2000 ◽  
Vol 45 (4) ◽  
pp. 299-303 ◽  
Author(s):  
Mirtha Grande ◽  
Kjell Carlstr�m ◽  
Barbro Lundh Rozell ◽  
Peter Eneroth ◽  
Reinhard Stege ◽  
...  
Keyword(s):  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Specific Antigen ◽  
Tissue Polypeptide Antigen ◽  
Tissue Concentrations

Transrectal Ultrasonography in the Diagnosis of Prostatic Carcinoma: Our Study on 365 Patients

1994 ◽  
Vol 61 (4) ◽  
pp. 270-276
Author(s):  
M. Calò ◽  
I. Malavolti ◽  
G. Cuscianna ◽  
F. Baldari ◽  
C.A. Pollastri ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Needle Biopsy ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
High Sensitivity ◽  
Transrectal Ultrasonography ◽  
Prostatic Specific Antigen ◽  
Clinical Exam

To evaluate the usefulness of transrectal ultrasound associated with needle biopsy of the prostate, 365 patients, with age ranging between 50 and 80 years, were studied for a total of 412 biopsies; the ultrasound exam was performed when the clinical or the prostate specific antigen findings were pathological. Our experience confirms the high sensitivity and specificity of transrectal ultrasonography in detecting prostate cancer. It is our opinion that all the patients with positive or negative digital rectal examination but altered prostatic specific antigen or clinical exam should undergo transrectal ultrasonography associated with needle biopsy. The elevated operability of the studied patients shows the capability of ultrasound to detect the pathology in the early stages and its value in screening diagnosis should therefore be considered.

PSA ed età

1994 ◽  
Vol 61 (1_suppl) ◽  
pp. 173-177
Author(s):  
R. Brigato ◽  
D. Griffa ◽  
A. Caputo ◽  
D. Surleti ◽  
M. Laudi
Keyword(s):  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Prostatic Specific Antigen

166 patients between 50-86 years old have been examimed for PSA immunoenzymatical determination (prostatic specific antigen). This group of patients has been divided into classes according to age (50-60, 61-70, 71-80) and urological pathology (107 with benign prostatic hypertrophy; 12 with histologically defined prostatic carcinoma without therapy; 15 with prostatic carcinoma incidentally determined after prostatic adenomectomy for benign prostatic hypertrophy and 32 patients with no prostatic urological pathology). We wanted to investigate how the PSA is correlated with age. The results of this study could demonstrate the importance of age for PSA interpretation. The low sensibility of this marker for the diagnosis of prostatic incidental carcinoma and low-class prostatic carcinoma could be shown with this study.

Association of goserelin and flutamide in the treatment of advanced prostatic carcinoma

1994 ◽  
Vol 61 (2) ◽  
pp. 111-115
Author(s):  
R. Minari ◽  
P. Salsi ◽  
B. Monica
Keyword(s):  
Prostatic Carcinoma ◽  
Performance Status ◽  
Specific Antigen ◽  
Hepatic Function ◽  
Prostatic Specific Antigen ◽  
Secondary Effects ◽  
Local Response ◽  
The Third ◽  
Initial Area ◽  
Lh Rh

From January 1987 to June 1990, 40 previously untreated patients, 60–85 years old (mean 76.7 years) with C and D stage (according to AUS) prostatic adenocarcinoma, were administered analogous LH-RH goserelin and the non-steroid antiandrogen flutamide. The patients were followed until June 1992. 9 patients died from the disease. The treatment was well tolerated in 68% of the cases (27 patients); in the other 13 patients, the administration of flutamide caused secondary effects (gastro-intestinal intolerance, alterations of hepatic function). The administration of goserelin did not cause any secondary effect. The local response (assessed by transrectal echography) was good and in 31 cases consisted of a regression of the initial area from 25 to 50%. The performance status improved in 16 patients. 12 patients had a remission of pain. In all the patients, from the third month of treatment, the testosteronemia remained under 0.8 ng/ml; the prostatic alkaline phosphatase and the prostatic specific antigen presented a good correlation with the clinical evolution of the disease.

scholarly journals IMMUNOHISTOCHEMICAL STUDY OF PROSTATIC ACID PHOSPHATASE AND PROSTATIC SPECIFIC ANTIGEN IN PROSTATIC CARCINOMA

1987 ◽  
Vol 78 (11) ◽  
pp. 1992-1997
Author(s):  
Nobuo Moriyama ◽  
Jun Taniguchi ◽  
Makoto Hara ◽  
Keiko Fukutani ◽  
Hisashi Matsushima ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostatic Carcinoma ◽  
Immunohistochemical Study ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Specific Antigen

A recent increase in the incidence of prostatic carcinoma in a French population: Role of ultrasonography and prostatic specific antigen

1995 ◽  
Vol 31 (1) ◽  
pp. 55-58 ◽  
Author(s):  
F. Ménégoz ◽  
M. Colonna ◽  
C. Exbrayat ◽  
M. Mousseau ◽  
H. Orfeuvre ◽  
...  
Keyword(s):  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
French Population ◽  
Prostatic Specific Antigen ◽  
Recent Increase

scholarly journals PROSTATIC CARCINOMA

2015 ◽  
Vol 22 (06) ◽  
pp. 710-714
Author(s):  
Mumtaz Rasool ◽  
Shafiq Ahmad Iqbal ◽  
Mudassar Saeed Pansota ◽  
Shafqat Ali Tabassum ◽  
Iftikhar Ahmad
Keyword(s):  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Case Series ◽  
P Value ◽  
Gleason Grade ◽  
Prostatic Specific Antigen ◽  
Advanced Carcinoma ◽  
Carcinoma Prostate ◽  
Case Series Study ◽  
Increased Risk

Introduction: During the past many years the availability of serum PSAas a screening marker, has encouraged its use to diagnose both prostatic cancer and itsrecurrence. Patients with high S/PSA are at increased risk of advanced carcinoma prostate andscreening at an earlier stage would help to manage it accordingly. The aim of this study wasto determine association between serum prostatic specific antigen (PSA) levels and Gleasongrade in prostatic carcinoma patients. Study Design: Descriptive, case series study. Setting:Department of Urology & Renal Transplantation in collaboration with Institutional laboratoryof Bahawal Victoria Hospital, Bahawalpur. Period: June 2012 to June 2014. Materials &Methods: Total 160 patients of age 50-80 years with biopsy proven prostatic carcinoma wereincluded. Patients with h/o radiotherapy for prostatic carcinoma and anti-androgen therapywere excluded. Histological slides of each patient were reviewed by using the Gleason gradingsystem. Gleason grade of each patient was correlated with his serum prostatic specific antigen(PSA) report which was done before surgery or biopsy. Results: In our study, mean age was66.89 ± 9.28 years. Mean serum PSA was 21.41 ± 13.67 ng/ml. Intermediate grade cancerwas found in 38.75% patients followed by moderate to poorly differentiated cancer in 31.86%patients. Gleason score ≥7 was significantly higher in patients with serum PSA >20 ng/mL thanthose with serum PSA ≤ 20 ng/mL (p-value of 0.000). So, serum PSA was positively correlatedwith gleason grade (OR = 3.67, Cl = 95%, P = 0.0001) Conclusion: This study concludedthat there is statistically significant association between serum prostatic specific antigen (PSA)levels and Gleason grade in prostatic carcinoma patients and patients with high prostatespecific antigen are at increased risk of advanced carcinoma prostate.

1263: Preoperative Prostatic Specific Antigen is Correlated with Tumor Volume and Prostate Weight and Predictive of Biochemical Recurrence

2004 ◽  
Vol 171 (4S) ◽  
pp. 332-333
Author(s):  
Paula J. Bunde ◽  
Michael O. Koch ◽  
Richard Bihrle ◽  
Thomas A. Gardner ◽  
John N. Eble ◽  
...  
Keyword(s):  
Biochemical Recurrence ◽  
Tumor Volume ◽  
Specific Antigen ◽  
Prostatic Specific Antigen ◽  
Prostate Weight
Sign in / Sign up

Export Citation Format

Share Document